The obvious caveat is that there was preclinical data to support the PD-1 combo, but they barely got a signal
Interesting. When I looked into this one, my personal conclusion was that the preclinical data rationalized a CTLA-4 combination but did not support a PD-(L)1 combination.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.